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Abstract
Latexin is a negative regulator of hematopoietic stem cell number in mice. Its dysregulated expression in other tumors led
us to hypothesize that latexin may have tumor suppressor properties in hematological malignancies. We found that latexin
was down-regulated in a variety of leukemia and lymphoma cell lines as well as in CD34+ cells from the blood and marrow
of patients with these malignancies. 5-aza-29-deoxycytodine treatment and bisulfite sequencing revealed hypermethylation
of latexin promoter in tumor cells. Retrovirus-mediated latexin overexpression in A20 mouse lymphoma cells inhibited their
in vitro growth by 16 fold and in vivo tumor volume by 2 fold. Latexin caused growth inhibition of lymphoma cells by
significantly increasing apoptosis through the down-regulation of anti-apoptotic genes Bcl-2 and Pim-2. The molecular
mechanism underlying latexin-mediated tumor inhibition was not through its canonical carboxypeptidase inhibitor activity.
These results are consistent with a tumor suppressor role for latexin and suggest that latexin may have clinical efficacy in
the treatment of malignancies.
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peripheral nervous systems [10]. Lxn was found to be involved in
the inflammatory response in macrophages owing to its paired
cystatin-like domains [11]. It was detected in mast cells associated
with a unique type of intracellular granule distinct from histaminecontaining secretory granules and lysosomes [12]. Lxn has about
30% sequence homology, but much greater structural homology,
with tazarotene-induced gene 1 (TIG1) (or retinoic acid receptor
responder 1, RARRES1), whose expression was down-regulated in
an extensive list of tumor types in humans. [11,13,14,15,16]. Lxn
and TIG1 are closely linked genetically and may represent
members of a family of functionally related genes. Moreover,
Lxn was reported to be a TNF-responsive gene in human
papillovirus-infected keratinocytes, suggesting that it may contribute to TNF-mediated suppression of cervical cancer development
[17]. A recent report revealed that Lxn was down-regulated in
patients with gastric carcinomas, and overexpression or knockdown of Lxn inhibited or stimulated tumor growth respectively
[18]. Decreased or absent Lxn expression was observed in several
human leukemia and lymphoma cell lines [19], as well as in
malignant melanoma patients. [20] However, there is still lack of
direct evidence for the cause-effect relationship between Lxn and
hematopoietic malignancy.
Gene silencing, especially of tumor suppressors, and inappropriate gene activation, especially of oncogenes, are common

Introduction
Both solid and liquid tumors are now understood to originate
from the malignant transformation of resident adult stem and
progenitor cells. [1,2] Nowhere is this paradigm better established
than in leukemia, yet events causing neoplastic conversion remain
poorly understood. [3] We identified latexin (Lxn) as a novel,
homeostatic regulator of the size of the hematopoietic stem cell
population in mice. [4] The stem cell pool size was inversely
related to quantitative Lxn expression at both the levels of
transcript and protein. We found that population size was
influenced by Lxn in a stem cell-autonomous manner, and acting
through the concerted mechanisms of self-renewal and apoptosis,
which were decreased and increased, respectively, by Lxn
abundance. [4] Thus, Lxn acts as a brake on the expansion of
stem cell population. Unrestrained stem cell expansion carries with
it the risk of mutations, genomic instability and carcinogenesis. We
therefore hypothesized that Lxn expression patterns in stem and
progenitor cells may act as a tumor suppressor by inhibiting stem
and progenitor cell proliferation, influencing the crucial steps
toward malignancy.
Lxn was primarily studied in the nervous system, involving the
specification of cortical brain regions during development
[5,6,7,8,9], as well as the speed of nerve transmission in adult
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themes in carcinogenesis. [21] Both often occur through aberrant
DNA methylation that is accentuated during aging.
[22,23,24,25,26,27] A CpG-enriched region was identified in
Lxn promoter and its hypermethylation was found in a variety of
human gastric carcinoma cell lines. [18] Promoter hypermethylation of TIG1 was also associated with its silencing in tumor cells.
[13,16] However, it is not known whether Lxn expression is
regulated by promoter methylation in hematopoietic malignancy.
Molecular mechanisms underlying the role of Lxn in regulating
hematopoiesis has not been determined yet. Lxn protein binds to
carboxypeptidase A (Cpa) and inhibits its enzymatic activity,
indicating that Lxn regulates protein degradation and metabolism.
[19] Lxn was highly expressed in mast cells and its expression was
further enhanced by LPS, indicating its potential function in
inflammation. [11] Proteomic analysis on Lxn knock-out hematopoietic cells revealed that Lxn deletion reduced the abundance of
multiple cellular proteins, especially those involving cell-stroma
interaction, such as N-cadherin, Tie2, and Roundabout 4. [19]
Ectopic expression of Lxn in gastric cancer cell lines led to the
differential expressions of several cancer-related genes, including
Maspin, WFDC1, SLPI, S100P, and PDGEFB [18], although
none of them are overlapped with previously mentioned proteomic
results. A recent study revealed ATP/GTP binding protein-like 2
(AGBL2) as a novel binding partner of TIG1. The interaction
between TIG1 and AGBL2 regulates the microtubule tyrosination
cycle, which is implicated in tumorigenesis, stem cell differentiation and development. [28] Lxn thus may have the similar
mechanisms as TIG1 to regulate hematopoiesis.
Here, we provide evidence obtained from a variety of
lymphoma and leukemia cell lines, as well as from primary cells
from patients with these diseases, that Lxn expression is almost
universally absent or significantly reduced from that of normal
stem and progenitor cells. Moreover, treatment with a demethylating agent at least partially restores Lxn expression in a
variety of tumor cell lines, and methylation level of the CpG island
in the Lxn promoter region is inversely associated with its
expression. Perhaps most importantly, we show that when Lxn
expression was re-initiated ectopically in two lymphoma cell lines
using a retroviral expression vector, their growth, both in vitro and
in vivo, was significantly blunted. We further show that Lxn inhibits
lymphoma cell growth by significantly increasing apoptosis
through the down-regulation of anti-apoptotic genes and that its
anti-tumor activity is mediated via mechanisms unique from its
canonical inhibition of carboxypeptidase A. These results demonstrate that Lxn plays a functional role in tumor cell growth and
introduces an unexplored pathway potentially important to cancer
treatment in patients.

Aberrant Promoter Hypermethylation of Lxn in
Hematopoietic Malignancy
To assess whether the loss or decrease of Lxn expression in
malignant cell lines resulted from promoter hypermethylation,
methylation of the 59 CpG island of Lxn gene surrounding its
transcriptional start site was determined by genomic bisulfite
sequencing. The CpG island spans from within the canonical 59
promoter (2208 nt) to the transcription start site (+1 nt), and
extends through the entire first exon (+44 nt). There are 15 CpG
dinucleotides within this region (Fig. 2A). The CpG island
identified here is not exactly same as the one reported previously,
this may be due to the different criteria we used for defining this
region. Figure 2B depicts the quantitative variation in methylation
for each CpG site among nine tumor cell lines. Almost complete
methylation was seen in J45.01, U937, Jurkat, Molt4 and CCRFCEM (.90%) lines, which commensurately showed an absence of
Lxn expression. Scatteredly methylated CpG sites were found in
K562, KG-1 and SupB15 lines, which were linked to the weak
expression of Lxn. Surprisingly, although HL-60 had very low Lxn
expression, we found that none of the CpG sites were methylated.
This is probably due to other epigenetic mechanisms, such as
histone deacetylation of latexin promoter in HL 60 cells.

Reactivation of Lxn Expression with Demethylating
Reagent Treatment
To test the hypothesis that Lxn promoter hypermethylation
might be involved in the loss of expression in leukemia and
lymphoma cell lines, we studied the effect of 5-aza-29-deoxycytidine, a DNA demethylating reagent, on Lxn expression (Fig. 2C).
After treatment with 2 uM 5-aza-29-deoxycytidine for 4 days, Lxn
gene expression was reactivated in cell lines completely lacking Lxn
expression prior to treatment (K562, Molt4, CCRF-CEM, J45.01,
Jurkat and U937), and was significantly up-regulated in HL-60,
KG-1 and SupB15 lines. The up-regulation of Lxn by 5-aza-29deoxycytidine in HL60 cells, which shows no hypermethylation of
CpG sties (Fig. 2B), might be because the demethylation of other
DNA sequences induces chromatin remodeling, thus exposing Lxn
promoter for the transcriptional initiation.

Suppression of Growth of Mouse Lymphoma Cell Lines in
vitro and in vivo Following Ectopic Lxn Expression
To determine a correlative or causative relationship between
Lxn expression and tumor development, we next asked whether or
not the re-initiation of Lxn expression affected the growth rate of
malignant cells in vitro and in vivo. To that end, we ectopically
expressed Lxn, using a retroviral expression vector containing
green fluorescent protein (GFP) marker, in the mouse BALB/cderived A20 B lymphoma cell line, which lacks Lxn expression
(Fig. 3C). The controls are A20 cells either un-infected or infected
with empty vector. The GFP positive A20 cells were purified by
flow cytometric cell sorting, and their growth was determined in
vitro and in vivo.
Fig. 3 shows the potent effects of Lxn expression on inhibiting
tumor growth in vitro and in vivo. Fig. 3A shows that cultures of A20
cells infected with the Lxn expression vector contained only about
half the number of cells at day 3 as compared to A20 cells infected
with the control (empty) vector or uninfected control cells (A20
control). The growth suppression by Lxn overexpression was
exponentially amplified during subsequent days of culture and by
day 20 nearly 16 fold less tumor cells were present in Lxnoverexpressing group than in control cultures (right panel). Fig. 3B
shows that the fraction of GFP+ cells remained at 90–100%
throughout the 20 days of culture in both the Lxn vector- or

Results
Loss of Lxn Expression in Malignant Cells
We first determined Lxn mRNA abundance in tumor cell lines
by quantitative real-time PCR (Fig. 1A). Compared with normal
primitive hematopoietic cells, Lxn mRNA expression was completely absent in a majority of tested leukemic lines, including
K562, Molt4, CRF-CEM, J45.01, Jurkat and U937, and was
significantly diminished in HL-60, KG-1 and SupB15 cell lines.
LXN protein expression was also tested in all samples using
Western blotting and nearly identical results were obtained in
tested cell lines (Fig. 1B). Our results are consistent with those
previously reported [19] and include additional leukemia and
lymphoma cell lines.
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Figure 1. Decrease or loss of Lxn expression in leukemic and lymphoma cell lines. (A) Lxn mRNA expression in leukemia cell lines. Lxn
mRNA level was measured by quantitative real-time PCR and shown as mean (61 SD) (n = 12). Control is normal bone marrow (BM). (B) Lxn protein
expression in leukemic cell lines measured by western blot. The blot (bottom) and their quantification (top) profiles demonstrate the absent or weak
expression of LXN protein in leukemic and lymphoma cell lines. Actin was used as the internal control.
doi:10.1371/journal.pone.0044979.g001

control vector-infected cells. Fig. 3C shows that at day 20 of
culture neither uninfected A20 cells nor A20 cells infected with the
control (empty) vector expressed detectable Lxn protein, whereas
in the Western blot a strong Lxn band was evident in lysate of cells
infected with the Lxn vector (upper band). LXN protein level at
day 0 of culture in these cells is nearly identical to that at day 20
(data not shown). In a separate series of experiments, we have
found a similar growth reduction in vitro when Lxn was ectopically
expressed in WEHI231 lymphoma cells (data not shown).
Fig. 3D shows a compilation of two independent experiments in
which ectopic Lxn expression suppressed the growth of A20 cell in
vivo. 100,000 GFP+ A20 cells infected with either the Lxn
expression vector or the GFP only control vector, or uninfected
A20 cells, were injected subcutaneously into the flanks of BALB/c
mice. Beginning at day 12 when tumors were first palpable, the
Lxn-expressing cells caused significantly smaller tumors (filled
circles; P,0.005). By day 21 when the experiments were
terminated, the tumors in the Lxn vector-injected group averaged
only 40% of the volume of tumors in the other two control groups
(P,0.05, n = 12 in each group). At day 21, we determined the
fraction of tumor cells expressing GFP and Fig. 3F shows that
virtually all of the tumor cells in the Lxn and control vector groups
were GFP+. More to the point, Western blots confirmed strong
expression of Lxn as in the cells analyzed after 20 days in culture
(Fig. 3C). Thus, the reduction in tumor growth was due to durable
Lxn expression in the tumor cells themselves.
To explore the effects of cell dose on tumor size and latency
before being palpable, we ejected graded doses of Lxn-expressing
or control A20 cells (Fig. 3E) to BALB/c recipient (n = 4/group).
At the 5,000 and 25,000 inoculum sizes, the Lxn-expressing cells
not only resulted in more impressive suppression of the size of
tumors than with the 100,000 cell inoculum in Fig. 3D, but
resulted in delayed onset of measurable-sized tumors. At day 21,
the reduction in tumor size caused by ectopic Lxn expression was
83% and 63% at the 5,000 and 25,000 cell doses, respectively.
Host animals were necropsied for evidence of gross metastases to
PLOS ONE | www.plosone.org

spleen, thymus and liver. No evident tumors were found in any of
the treatment groups. Similarly, flow cytometry detected no GFP+
cells in these anatomical sites (data not shown).

Lxn Inhibits Tumor Cell Growth through Increasing
Apoptosis but not via its Canonical Function
As we previously reported in our normal hematopoietic stem
cell studies, high Lxn expression is associated with increased
apoptosis and decreased proliferation. To determine if these
mechanisms were applied to our results with tumor cells, we next
measured these two parameters in vector-infected A20 cells
throughout 21 days of culture. As shown in Fig. 4A, flow
cytometric analysis of cells stained with BrdU and 7AAD allows
for the discrimination of cell subsets that are apoptotic (A), necrotic
(N) or reside in G0/G1, S and G2/M phase of cell cycle. By day 5
of culture, 10 fold more Lxn-expressing tumor cells were
undergoing apoptosis than control cells (10.6% vs 1%). NO
significant differences in the proliferation and the numbers of
necrotic cells were observed between Lxn-overexpressing and
control cells (data not shown). These results point to apoptosis as
the major cellular mechanism in Lxn-mediated tumor suppression.
We next investigated the molecular mechanisms underlying Lxninduced apoptosis. We performed apoptosis pathway-specific PCR
arrays in A20 cells infected with either empty or Lxn-expressing
vectors. We found that 17 out of 84 apoptosis-related genes were
differentially expressed in Lxn-overexpressing cells, and majority of
them (15 genes) were down-regulated (data not shown). We
specifically examined several well-known apoptotic genes, such as
Bcl-2, Pim-2, Bcl-xl, Bax, and Bad, and plotted their expression in
Fig. 4B. Two anti-apoptotic genes, Bcl-2 and Pim-2, were downregulated by at least 3-fold in Lxn-overexpressing cells (left panel)
as compared to the control, whereas pro-apoptotic genes,
including Bax and Bad, did not show any change in their mRNA
levels. Western blots of these proteins observed the similar
reduction in Bcl-2 and Pim-2 (all three isoforms) but not in Bclxl, Bax and Bad in Lxn-overexpressing A20 cells (right panel),
3
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Figure 2. Hypermethylation of Lxn promoter CpG sites in leukemic cell lines. (A) CpG-enriched region in Lxn promoter. Sequence from
1500 base pairs upstream regulatory region to the first three exons was analyzed for CpG-enriched sites (top). A CpG island with 252 base pairs (bps)
length was identified. The transcription starting site is indicated. Each filled circle represents a CpG dinucleotide, and there are 15. (B) Bisulfite
sequencing for Lxn promoter CpG island methylation analysis in leukemic cell lines. Files are each of the 15 CpGs and ranks are replicate clones
sequenced for each CpG (n = 3). Open circles indicate unmethylated CpG (n = 3) dinucleotides. Filled circles indicate methylated CpG dinucleotides.
The methylation content was quantified by dividing the number of methylated CpGs with total numbers of analyzed CpGs. (C) Restoration or up-
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regulation of Lxn expression by 5-aza-29-deoxycytidine. Lxn mRNA was measured by quantitative real-time PCR in leukemic and lymphoma cell lines
exposed with or without 2 uM 5-aza-29-deoxycytidine for 4 days. Expression levels were normalized to endogenous control, Gapdh. Results shown are
mean6 SD of 12 replicates from 3 independent experiments.
doi:10.1371/journal.pone.0044979.g002

expression at the protein level is more variable than that at the
mRNA level. Two additional old samples in the normal control
group contribute to this variation, which is consistent with the
report that the number and functionality of HSCs in old
individuals, perhaps stem cell regulatory gene(s), showed more
dramatic variations as compared to their young counterparts [30].
In summary, these data indicate that Lxn dysregulation may be
involved in human hematological malignancies. In the future
study, it will be interesting to examine the expression of two antiapoptotic genes, Bcl-2 and Pim-2, in patient samples to see
whether or not they are up-regulated.

which is consistent with PCR array result. Thus our data indicate
that Lxn-induced apoptosis in A20 cells is mainly through the
down-regulation of anti-apoptotic regulators, such as Bcl-2 and
Pim-2.
A well-known function of Lxn is its role as the sole carboxypeptidase A (CPA) inhibitor in mammalian cells. There are six Cpa
genes (1–6) in this family. In order to test whether or not the
suppressive effect of ectopic Lxn expression on the growth of A20
and WEHI231 cells was due to its canonical inhibitory activity, we
carried out the following experiments. We first determined which
Cpa genes are enriched in hematopoietic stem/progenitor cells. By
searching our gene expression profile of hematopoietic stem/
progenitor cells (unpublished data), we found that Cpa3 is the only
gene highly expressed in hematopoietic cells (Table S1). Next, we
tested Cpa3 expression in A20 cells that were uninfected, or
infected with empty or Lxn expression vectors, and found that it
was not expressed in any type of these cells (Figure S1). Last, we
treated A20 and WEHI cells with potato carboxypeptidase A
inhibitor (PCPI), a 39 amino acid protein which strongly inhibits
mammalian CPA, at a series of concentrations ranging from 5 to
60 ug/ml of culture medium. As seen in Fig. 4C, none of the
concentrations had any effect on the growth patterns of the tumor
lines, despite the continuous presence of PCPI for 12 days of
culture. To rule out the possibility that PCPI failed to inhibit
tumor growth because it did not enter the cells, we used fluorescein
isothyiocyanate (FITC) to label PCPI in cells. Fig. 4D shows A20
cells following a 30 min incubation with labeled PCPI (30 ug/ml
of culture medium). The three-color micrograph shows PCPI in
green (FITC), the nucleus in blue (DAPI), and the B220 lymphoid
cell surface marker in red (phycoerythrin, PE). It is apparent that
PCPI is plentiful in the cytosol but is not found in the nucleus. The
doses of PCPI chosen for the above experiments were taken
directly from a study in which the inhibitor was shown to inhibit
the growth of pancreatic adenocarcinoma cells by directly
interfering with the epidermal growth factor signaling pathway
[29]. Maximal growth inhibition was achieved at 30–50 ug/ml.
Thus, the mechanisms by which Lxn regulates both stem cell
population size and lymphoma growth inhibition reside in a novel
pathway involving apoptosis.

Discussion
Recently we found that Lxn is a natural regulator of
hematopoietic stem cell population in mice by influencing selfrenewal and apoptosis [4]. Lxn expression in stem cells is inversely
proportional to the size of the population in mice and thus acts as a
negative regulator through cell-intrinsic mechanisms. The observation that low Lxn expression in hematopoietic cells was
associated with increased replication led us to hypothesize that
Lxn was down-regulated in malignancies with high proliferative
rates and/or low apoptosis.
Here, we show that Lxn is either not expressed or is strongly
down-regulated in a variety of leukemias and lymphomas. As a
result of these findings and close linkage structurally and
genetically with TIG1, we proposed that Lxn may similarly act
as a tumor suppressor. Along with this proposal, there is
expectation that manipulation of Lxn levels in malignant cells
would alter their growth characteristics. Accordingly, two
lymphoma cell lines in which Lxn expression was absent were
infected with a Lxn expression vector. In one of the most significant
findings of this study, we found that re-initiation of Lxn expression
dramatically reduced their growth in vitro and in vivo. These results
demonstrate that the level of Lxn expression is functionally related
to both normal and malignant cell growth and, if the findings are
true for human tumors, may provide an avenue for therapeutic
intervention. Surprisingly, Lxn knock-out mice did not development leukemia nor lymphoma even though their hematopoietic
stem cell pool was over-expanded and blast cells were detected in
the peripheral blood [19]. These results suggest that Lxn may
influence the crucial, step in carcinogenesis [31]. It thus will be of
great interest to introduce additional carcinogenetic ‘‘hits’’, such as
oncogenes or alkylating agents, to Lxn knockout stem cells to
determine whether Lxn deletion will accelerate tumor development. In addition, we observed that re-initiation of Lxn expression
did not completely suppress tumor cell growth, suggesting that it
would at best be a part of a multi-drug regimen.
We investigated the possible mechanisms by which ectopic Lxn
expression may suppress growth of lymphoma cells and found
increased apoptosis to be the major mechanism causing inhibition.
Consistent with our study of normal hematopoietic cells, our
recent findings indicate that high Lxn content is associated with
more apoptotic cells, thus fewer stem cells [4]. Apoptosis is
controlled by the balance of both positive (pro-apoptotic) and
negative (anti-apoptotic) signals. We found that Lxn-induced
apoptosis is mainly through the down-regulation of anti-apoptotic
genes, such as Bcl-2 and Pim-2. Decreased level of Bcl-2 allows
other pro-apoptotic proteins such as BAX and BAK to aggregate,

Down-regulation of Lxn in Primary Leukemia and
Lymphoma Cells
Based on the strong evidence for the tumor suppressive function
of Lxn in leukemia and lymphoma cell lines, we asked whether or
not Lxn expression is altered in primary cells derived from patients
with malignancies. We isolated stem/progenitor-enriched CD34+
cells from bone marrow and blood cells in lymphoma and
leukemia patients, as well as in normal donors. The patients
included those with acute myeloid leukemia (AML), T cell prolymphocytic leukemia (T-PLL), plasma cell leukemia (PCL), acute
T cell lymphoma (ATLL) and acute lymphoid leukemia (ALL,
preB phenotype). The normal CD34+ cell samples were derived
from cord blood (CB) and young (31 and 35 years) and old (85 and
97 years) adults. Lxn mRNA expression, quantified by real-time
PCR, was decreased by at least two-thirds in primary malignant
CD34+ cells (Fig. 5A). Quantification of LXN in CD34+ cells of
all human normal and leukemic samples compiled to date is
plotted in Fig. 5B. The result shows a significant decrease of LXN
protein expression in malignant cells (P = 0.03) even though Lxn
PLOS ONE | www.plosone.org
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Figure 3. Overexpression Lxn suppresses growth of A20 lymphoma cell lines. (A) In vitro growth inhibitory effects of Lxn overexpression on
A20 cells. A20 cells uninfected (A20 control) or infected with empty (vector control) or Lxn-containing vector (Lxn vector) were cultured for 20 days
and counted by the trypan blue exclusion method. The absolute cell numbers at indicated time-points (X axis) were represented as log scale (Y axis)
and were shown in left panel. The relative tumor growth in Lxn-overexpression A20 cells to controls was shown in the right panel. One representative
experiment out of 3 independent ones is shown. (B) Proportion of GFP+ A20 cells infected with empty (light grey column) and Lxn-containing vector
(black column) throughout 20 days of culture. Flow cytometric analysis was performed to detect GFP signal. (C) Western blot analysis with LXN
antibody in total protein lysate from A20 cells at day 20 culture showing durable LXN overexpression. (D) In vivo tumor formation and growth with
injection of 100,000 A20 cells. A20 cells were subcutaneously injected and tumor growth was monitored and measured by all three dimensions of
tumors (Y axis) on days indicated on X axis. Shown is the compilation of 2 independent experiments with 6 SD (n = 12). The statistical significance is
represented by * (p,0.005) and ** (p,0.05). (E) In vivo tumor formation and growth with injection of graded doses of A20 cells. Graded doses of A20
cells (X axis) were subcutaneously injected and tumor growth was monitored and measured in all three tumor dimensions (Y axis) on days indicated
on Z axis. Unfilled columns represent A20 cells infected with empty vector and filled columns represent cells with Lxn-containing vector. A
representative experiment is shown (n = 4/group). (F) The fraction of GFP-expressing A20 cells in tumors biopsied at 21 days. Single tumor cell
suspensions were made on day 21 post injection and subject to flow cytometric analysis for GFP-expressing cells.
doi:10.1371/journal.pone.0044979.g003

inducing cytochrome C release and caspase activation, and
apoptosis. Dysregulation of Bcl-2 is implicated in a variety of
hematopoietic malignancies. [32] Three Pim-2 protein isoforms
are active kinases which phosphorylate pro-apoptotic protein BAD
and dissociate its binding from Bcl-xL, resulting in the inhibition of
Bad-induced cell death. [33,34] Enhanced expression of Pim-2
was detected in multiple B-cell lymphoma types [35], T-cell
lymphoblastic leukemia/lymphoma [36], and acute myeloid
leukemia [37]. Thus our studies identify Lxn as a novel regulator
of the apoptotic pathway, in which it suppresses tumor survival
through the down-regulation of Bcl-2 and Pim-2 anti-apoptotic
factors.
The well- known function of Lxn is the sole carboxypeptidase A
inhibitor in mammals. [12] Therefore, it was plausible that other
carboxypeptidase A inhibitors might mimic Lxn’s anti-tumor
effects. A CPA inhibitor from potato tubers has been shown to
be an effective inhibitor of mammalian CPA and was therefore
chosen to test its anti-tumor properties. We found that it freely
entered A20 lymphoma cells but did not have suppressive growth
effects via apoptosis, irrespective of dose. Since CPAs are not
expressed in A20 cells, we conclude that non-canonical functions
of Lxn were responsible, yet unknown intracellular functions of Lxn
account for its anti-tumor effects. In addition, it is unlikely that
tumor suppressive effect of Lxn is through the regulation of
ABGL2-mediated microtubule tyrosination cycle, like TIG1,
because we did not detect the expression of ABGL2 in
hematopoietic cells (data not shown). These results are in line
with findings of other investigations in which gene expression or
protein abundance regulated by Lxn were not related to
carboxypeptidase inhibition [18,19]. Thus, the action of mode of
Lxn in regulating normal and malignant hematopoiesis is not
through its canonical CPA inhibitor activity. Future studies aimed
at identifying direct targets, or downstream signaling pathways, of
Lxn will be critical for our understanding of its function in normal
and malignant hematopoiesis.
Addressing the issue of why and how Lxn expression is downregulated in tumor cells, we found that CpG dinucleotides in
regulatory regions of the Lxn gene were methylated. Most human
leukemia and lymphoma cell lines tested showed strong patterns of
methylation involving most of the 15 CpG dinucleotides in Lxn
promoter. This, in turn, led to a loss of gene expression that was at
least partially reversible. When cell lines were treated with demethylating reagent, 5-aza-29-deoxycytidine, Lxn expression was
re-initiated or up-regulated. Thus, hypermethylation of the CpG
island in the Lxn promoter may contribute to silencing or downregulation of Lxn expression in leukemia and lymphoma cells.
Ongoing studies will focus on the genetic and epigenetic regulation
of Lxn transcription in cancer stem cells, with promise for
improved targeted approaches for cancer prevention, diagnosis,
and therapy.
PLOS ONE | www.plosone.org

Materials and Methods
Animals
Young 8-to 12- week old female C57BL/6 (B6) and 7-week old
female BALB/c mice were purchased from the Jackson Laboratories (Bar Harbor, ME). Mice were kept in the animal facilities of
the University of Kentucky under pathogen-free conditions
according to NIH-mandated guidelines for animal welfare. They
were fed with acidified water and food ad libitum. All animal work
in this study was approved by Institutional Animal Care and Use
committee (IACUC) at the University of Kentucky (Identification
number: 2010-0753).

Leukemia Cell Lines
Nine human leukemic cell lines (K562, Molt4, CCRF-CEM,
J45.01, Jurkat, U937, HL-60, KG-1 and SupB15) and two mouse
lymphoma cell lines (WEHI-231 and A20) were included in our
study. Human leukemic cell lines were purchased from American
Type Culture Collection (ATCC) (Manassas, VA). Mouse
lymphoma cell lines are gifts from Dr. Bondada [38]. The
leukemia cell lines were maintained in IMDM supplemented with
either 10% (K562) or 20% (KG-1, HL-60 and Sup-B15) fetal
bovine serum (FBS), or RPMI medium with 10% FBS,
10 mM Hepes (Molt4, CCRF-CEM, J45.01, Jurkat and U937),
0.05 mM 2-mecaptoethanol, 80 U/mL penicillin, and 80 mg/mL
streptomycin. The cells were incubated in a humidified atmosphere of 5% CO2 in air at 37uC.

Isolation of CD34+ Cells
Primary AML cells were obtained from the peripheral blood
and bone marrow of patients at the Markey Cancer Center and
Northwestern University. Normal bone marrow was obtained as
discarded material following pathologic analysis, surgical marrow harvest, or from the National Disease Research Interchange
(NDRI). CB was obtained from patients at the University of
Kentucky Obstetrics Department or from the NDRI. All tissues
were obtained with the approval of the respective institutional
review boards and appropriate informed consent (confirmation
number is 11-0315-F3R from University of Kentucky). Some
samples were collected form Northwestern University and
transferred to University of Illinois at Urbana-Champaign with
approval of Material Transfer Agreement (MTA). We processed
9 normal and 9 leukemia and lymphoma samples, the age and
disease type of each sample was described in the figure 5
legends. Marrow and blood cells were depleted of erythrocytes
by suspending in 150 mM NH4Cl plus 10 mM NaHCO3 for 5
minutes, followed by 2 washes with phosphate-buffered saline
(PBS). Blood cells were subjected to Ficoll-Paque (Pharmacia
Biotech, Piscataway, NJ) density gradient separation to isolate
7
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Figure 4. Ectopic Lxn expression increases apoptosis of A20 cells. (A) Flow cytometric analysis of cell cycle and apoptosis in cultured A20
cells. A20 cells without (A20 control) or with empty (vector control) or Lxn-containing vector (Lxn vector) were cultured for 21 days. BrdU and 7AAD
staining and flow cytometric analysis was used for detecting different phases of the cell cycle (G0/G1, S, G2/M) and apoptotic (A) and necrotic (N)
population. A representative flow cytometric file from Day 5 of culture is shown. (B): Down-regulation of anti-apoptotic genes by Lxn overexpression.
Apoptosis PCR arrays were performed on A20 cells infected with empty or Lxn-expressing vectors. Left panel shows the fold changes in the mRNA
expression of several selected genes (as indicated in X axis) in Lxn-overexpressing cells compared to the control. Western blot confirms the decreased
expression of Bcl-2 and two isoforms of Pim-2 at the protein level in Lxn-overexpressing cells (arrowhead). The other apoptosis-related genes, such as
Bcl-xl, Bax and Bad, did not show significant difference in mRNA and protein expression. (C) The growth curve of A20 cells treated with graded doses
of potato carboxypeptidase inhibitor (PCPI). No significant difference is detected between the control and any of the doses of PCPI. (D) Internalization
of PCPI to cytosol of A20 cells. A20 cells were cultured with fluorescein isothiocyanate (FITC) labeled PCPI. Shown is a three-color micrograph with
PCPI in green (FITC), the B220 lymphoid cell surface marker in red (phycoerythrin, PE), the nucleus in blue (DAPI), and merged image of red and green
as indicated.
doi:10.1371/journal.pone.0044979.g004

the mononuclear white blood cell compartment. Resulting
leukocytes from marrow or blood were then used for
immunoaffinity selection and flow cytometric sorting. For
CD34+ cell selection, the Miltenyi immunoaffinity device
(VarioMACS) was used according to the manufacturer’s
instructions (Miltenyi Biotech, Auburn, CA), and further
purified by immune-staining with anti-CD34 antibodies (Pharmingen, San Diego, CA) and sorting in a triple-laser
FACSVantage flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA). In some cases, leukocytes were
cryopreserved at a concentration of 56107 cells/mL in freezing
medium consisting of Iscoves modified Dulbecco medium
(IMDM), 40% fetal bovine serum (FBS), and 10% dimethyl
sulfoxide (DMSO).

Quantitative Real-time PCR
To measure the expression of Lxn in leukemic cells, quantitative
real-time PCR was performed. Identical numbers (200,000) of cells
were used for total RNA extraction using RNeasy Mini kit
(QIAGEN, Valencia, CA) according to the manufacture’s
instruction. Isolated total RNA was reverse transcribed into
cDNA using random hexamers in a TaqManH reverse transcription solution (PN N8080234) and stored at 220uC. In real-time
PCR reactions, primer and probe mix for LXN (human and
mouse) were purchased from Applied Biosystems (Foster city, CA,
USA). TaqManH human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was served as an endogenous control to normalize
LXN expression. PCR reactions were set up according to
manufacturer’s instructions using TaqManH universal PCR master
mix (PN 4304437). Analyses of gene expression were performed in

Figure 5. Decreased Lxn expression in stem/progenitor-enriched CD34+ cells in patients with leukemia and lymphoma. (A) Lxn mRNA
expression in bone marrow and peripheral blood CD34+ cells from leukemia and lymphoma patients and normal individuals. Lxn mRNA level was
measured by quantitative real-time PCR and shown as mean (61 SD) (n = 12). Normal samples were derived from cord blood (CB), bone marrow (BM)
of young at 31 (Y1) and 39 (Y2) years old and old at 85 (O1) and 97 (O2) years old people. The patient samples include acute myeloid leukemia (AML),
T cell pro-lympho leukemia (Pctl), plasma cell leukemia (PCL), acute T cell lymphoma (ATLL) and acute lymphoid leukemia (ALL, preB phenotype). (B)
LXN protein expression in bone marrow and peripheral blood CD34+ cells from leukemia and lymphoma patients and normal individuals. Western
blot was performed on the corresponding samples shown in panel (A) plus five more samples, including two young (Y3 and Y4; at 40 and 31 years
old respectively), two old (O3 and O4; at 80 and 87 years old respectively) and chronic myeloid leukemia (CML). The blots (bottom) and their
quantification (top) profiles demonstrate the significantly decreased Lxn protein level in leukemic CD34+ and lymphoma cells (P = 0.03).
doi:10.1371/journal.pone.0044979.g005
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aspx) showed a 252 bp region (–208 bp to +44 bp) in upstream
of Lxn sequence enriched for CpG repeats. The criteria of 5 CpG
island is: GC content .50%, ratio of CpG to GpC .0.6 and
200 bp of minimum length. Genomic DNAs were isolated using
AquaPure Genomic DNA kit (Bio-Rad, Hercules, CA) and
modified by sodium bisulfite using EpiTectH Bisulfite kit (QIAGEN, Valencia, CA). For the Lxn promoter methylation study, we
designed primers that could amplify a 423 bp fragment in the
upstream region of Lxn containing CpG island. The forward
primer sequence is 59 GTTGGTGTTTGATAAGTATGTGG
39, and the reverse primer sequence is 59 TTTAACCTTCTACACCTCAAACAC 39. The annealing temperatures for primers
were 52uC for 2 minutes. Hot-start PCR with a total cycle number
of 30 was used in all PCR amplifications. Denaturation and
extension cycles were maintained for 95uC, 30 seconds and 72uC,
1 minutes respectively. The amplified fragments were cloned into
the pCR2.1-TOPO vector using TOPO TA Cloning Kit
(Invitrogen Carlsbad, CA) and sequenced (MWG Technology)
(n$ 3 clones for cell line and n$ 8 clones for primary cells).

single reporter assays in an ABI PRISM 7700 sequence detection
system (PE Biosystems, Foster city, CA, USA).
RT2 Profiler Apoptosis PCR Array (PAMM-012Z, QIAGEN)
was performed according to the manufacture’s instructions.
cDNAs was prepared from A20 cells infected with empty or lxn
expression vectors with RT2 First Strand cDNA Kit (C-03,
QIAGEN) and added to RT2 qPCR master mix (PA-012). The
mixture was aliquoted across the PCR array which contains 84
apoptosis-related genes. Gene expression and quantification was
performed in an ABI PRISM 7700 sequence detection system, and
data was analyzed with using web-based software (http://
pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php).
The
genes with more than 2-fold change in expression and showing
statistically significant (p,0.05) were chosen for candidate gene.

Western Blots
Cell samples were lysed at a concentration of 26107 cells/ml in
a protein lysis buffer containing: 10 mM Tris pH 7.5,
50 mM NaCl, 30 mM sodium pyrophosphate, 50 mM NaF,
5 mM ZnCl2 and 1% Triton X-100, 2.8 ug/ml aprotinin
(Sigma-Aldrich; St. Louis, MO), 1 mM phenylmethylsulfonyl
fluoride (Sigma), 1 mM sodium vanadate (Na3VO4) 1 ug/ml
pepstatin, and 1 mg/ml leupeptin (Oncogene Research, MA,
USA). Lysate was incubated on ice for 30 min, and then
centrifuged at 15,0006g for 10 minutes to remove debris. The
resulting supernatant was then aliquoted and stored at 280uC. For
Western blot, protein lysates were thawed and mixed with running
buffer and a reducing agent (Novex, San Diego, CA, USA, per
manufacturer’s instructions) and heated at 95uC for 5 minutes.
Samples were then analyzed by denaturing PAGE (Novex, 10%
bis-Tris gel) using the equivalent of 46105 cells per lane. Following
electrophoresis, samples were electro-transferred onto immunobilon-P membranes (Millipore, Bedford, MA, USA), which were
subsequently blocked and probed with polyclonal rabbit anti-LXN
Ig-G antibody at a 1:3000 dilution. This antibody was generated
from the Lxn-specific amino acid sequence CKHNSRLPKEGQAE at the carboxyl terminus, and was produced by Bethyl
Laboratories, Inc. (Montgomery, TX). The antibody for detection
of human LXN was purchased from Abcam Inc. (Cambridge,
MA) and used at 1:2000 dilution. The antibodies for apoptotic
proteins, Bcl-2, Bcl-xl, Bax, Bad were provide by Dr. Bondada.
The antibody for Pim-2 was purchased from eBioscience (San
Diego, CA). Primary antibodies were detected using alkaline
phosphatase-conjugated secondary antibodies (Santa Cruz Biotechnology) and electro-chemifluorescent (ECF) reagent (Pharmacia Biotech) according to the manufacturer’s instructions. Blots
were visualized using a Molecular Dynamics STORM 860 system
and Imagequant Software. Following the detection and quantification of anti-LXN antibody, immunobilon-P membrane was
sequentially stripped in 40% methanol and the buffer containing
100 mm ß-mercaptoethanol, 2% sodium dodecyl sulfate and
62.4 mM Tris-HCl to remove ECF reaction product and
antibodies, respectively. The stripped membrane was re-probed
with anti-actin antibody (Sigma) at 1:500,000 dilution and
detected as described previously.

5-aza-29-deoxycytidine Treatment
To examine the correlation of promoter hypermethylation and
Lxn gene expression, the leukemia cell line, shown to have a lack or
decrease of Lxn expression, was subject to 5-aza-29-deoxycytidine
treatment. Cells were plated with 2 uM 5-aza-29-deoxycytidine
(Sigma-Aldrich; St. Louis, MO) and incubated for 4 days. The
medium and the drug were replaced every 24 hours (hrs.) and cells
were harvested for RNA and DNA extraction 4 days after
treatment.

Infection of WEHI231 and A20 Cells with Lxn Expression
Vector
Cloning of the mouse Lxn gene into Sfbeta 91 retroviral vector
and production of viral supernatant were performed exactly as
described previously [4]. WEHI-231 and A20 cells were infected
by 10 ml viral supernatant at a density of 16106 cells per 10 cm
plate along with 4 mg/ml of polybrene for 48 hours. The infected
cells (GFP+ cells) were sorted and expanded in culture medium.
The expanded GFP+ population, if not used immediately, was
cryopreserved at a concentration of 16107 cells/mL in freezing
medium consisting of 80% fetal bovine serum, and 20% dimethyl
sulfoxide (DMSO).

Measurement of Growth of Retrovirally-transduced
Tumor Cells
Sorted GFP+ A20 cells over expressing Lxn or Sfbeta 91 empty
vector were counted on a hemacytometer using trypan blue dye
exclusion and 500,000 cells were seeded into 25 cm2 tissue culture
flask in 4 mls media. Cells were incubated in a humidified
atmosphere of 5% CO2 in air at 37uC and subsequently counted
on days 3, 8, 12, 16 and 20. At each time point, cells were split and
maintained at a concentration of 500,000 cells per 4 ml media.
The cumulative cell number was calculated from the cell counts
and the dilutions made at each culture split. FACS analysis was
also performed at each time-point to measure the percentage of
GFP+ cells. For the in vivo measurement of tumor cell growth,
various numbers (5,000; 25,000; 50,000 and 100,000) of GFP+
A20 cells over expressing Lxn or Sfbeta 91 empty vector were
injected in a 50 ml bolus subcutaneously in the shaved flank of
BALB/cJ mice given 3.0 Gy of gamma radiation 4 hrs. prior.
Lymphomas were detectable by palpation 10–12 days postinjection and all three dimensions of tumors were measured blind
with calipers on days 12, 14, 16, 19, and 21. The same individual

Genomic Bisulfite Sequencing
To investigate the methylation pattern of Lxn promoter, CpG
island analysis in the upstream sequence of Lxn open reading
frame. Nucleotide sequence of Lxn in upstream region (–1000 bp)
and the first 3 exons (+373 bp) was obtained from Ensembl
database
(www.ensembl.org)
with
ID
number
ENSG00000079257. CpG island search using CpG island
searcher website (http://www.uscnorris.com/cpgislands2/cpg.
PLOS ONE | www.plosone.org
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made the measurements from day-to-day without knowing the
treatment regimen the mice received. At day 21, host mice were
euthanized, the lymphomas were excised, and single cell
suspensions were made of each to determine the fraction of tumor
cells expressing GFP.

calculated from the cell counts and the dilutions made at each
culture split.

Statistical Analysis
Data were analyzed by either student t-test assuming unequal
variance with P,0.05 (two-tail), or a one-way ANOVA.

Cell Cycle and Apoptotic Analysis
The culture of GFP+ A20 cells was maintained as described
above. At each time-point, cell cycle analysis was measured by
BrdU labeling using BrdU Flow Kit (Pharmingen, San Diego, CA)
according to the manufacturer’s instruction. 10 ul of BrdU
solution (1 mM) was added to 16106 cells in 1 ml culture medium
and incubated for 1 hour. The cells were fixed and permeabilized
by Cytofix/Cytoperm Buffer and treated with 30 ug DNase for 1
hour at 37uC. After washing with Perm/Wash buffer, cells were
stained with PE-conjugated anti-BrdU antibody for 20 minutes at
room temperature, washed and 20 ul of 7-AAD was added. The
cells were analyzed by flow cytometry on Facscan (Becton
Dickinson Immunocytometry Systems, San Jose, CA).

Supporting Information
Figure S1 Cpa3 is not expressed in A20 cells. Real-time
PCR was performed on A20 cells that were either uninfected (A20
control) or infected with empty (vector control) or Lxn expression
vector (Lxn vector) to quantify Cpa3 mRNA expression. The
amplification plots for Lxn (A), Cpa3 (B) and Gapdh (C) transcript
show that Lxn is highly expressed in A20 cells infected with Lxn
expression vector whereas A20 and vector controls have very low
expression levels, consistent with the results in Fig. 3c. Cpa3
transcript is not amplified in all types of cells, indicating it is not
expressed in A20 cells. These figures show the amplification plots
of four individual biological replicates (n = 4) for each gene.
(TIF)

Immunohistochemstry of A20 Cells Treated with Potato
Carboxypeptidase Inhibitor (PCPI)

Table S1 Carboxypeptidase A3 (Cpa3) is highly expressed in stem/progenitor cells. Expression level of CPAs
were measured by microarray on a bone marrow population null
for cell markers characteristic of lineage-specific differentiated
blood cells (Lin-negative), and positive for the Sca-1 and c-Kit cell
markers (LSK) cells, enriched for hematopoietic stem/progenitor
cells in mouse. The isolation of LSK cells as well as microarray
analysis was performed as previously described [38] except the
array platform is mouse Genome 430 2.0 Array (Affymetrix).
Three biological samples were assayed, and the mean expression
value (mean_y_B6) for each gene in the table is the average of
three readings. Cpa3 (highlighted in gray) is the only Cpa gene that
is highly enriched in LSK cells. Gapdh is the endogenous control.
(PDF)

PCI was purchased from Sigma-Aldrich Co. (St. Louis, MO).
FITC labeling of PCI was performed by using FLUOROTAGTM
FITC CONJUGATION KIT (Sigma-Aldrich) according to
manufacturer’s instruction, and was used to treat A20 cells for
fluorescence internalization assays. Cells are cultured on
22622 mm microscope cover glasses (Fisher Scientific Co.,
Pittsburgh, PA) in media as described above. Cells were fixed
onto cover glasses with 1:1 methanol:acetic acid and washed 3
times by PBS. Cells were incubated with FITC-conjugated PCI at
a concentration of 30 ug/ml at 37uC for 30 minutes, washed and
stained with phycoerythrin (PE)-conjugated B220 and DAPI. The
cover glass coated with A20 cell monolayer was flipped
immediately and sealed onto glass slide. The image was taken
with a Zeiss Axiovert- 200 microscope using a high-resolution
Zeiss digital camera (Carl Zeiss Inc., Thornwood, NY).
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